ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Despite the advancement in targeted molecular suppression of the oncogenic driver BCR-ABL in CML, the greater numbers of patients still need to prolong the treatment of tyrosine kinase inhibitor (TKI).210